A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma

NCT01989325 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Multiple Myeloma

Interventions

DRUG: Carfilzomib, proteasome inhibitor; intravenous
DRUG: Filanesib, KSP(Eg5) inhibitor; intravenous
DRUG: Dexamethasone, steroid; oral or intravenous
DRUG: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Sponsor

Pfizer